Replimune Group Inc

Replimune Group Inc maintains a strong liquidity position, with a current ratio of 7.95 and cash and equivalents of $111.1 million, indicating the company has sufficient short-term assets to cover its liabilities. The company's debt-to-equity ratio is 0.17, suggesting a conservative capital structure with limited leverage. However, the company's free cash flow is negative at -$248.06 million, reflecting ongoing operational cash outflows. The company's profitability metrics are negative, with a return on equity of -59.47% and a return on assets of -44.85%, indicating that it is not generating returns for shareholders or effectively utilizing its assets. Operating income and net income are both negative, at -$261.63 million and -$247.30 million, respectively, highlighting the company's current unprofitability. Replimune does not disclose segment or geographic revenue breakdowns in the available data, so it is not possible to assess revenue concentration or geographic exposure at this time. The company's growth trajectory is not clearly defined in the available data, but the negative operating and net income suggest that the company is not currently generating positive earnings. The company's risk assessment indicates low liquidity and dilution risk, with no immediate filing-based liquidity or dilution flags detected. The company's dilution potential is also low, and no adjustments have been applied to the valuation metrics. Recent events, such as filings or transcripts, are not detailed in the available data. Analyst estimates for Replimune show a mean price target of $4.94 and a median price target of $2.00, with a mean recommendation of 3.12, indicating a mixed outlook from analysts. The high price target of $14.00 and the low price target of $1.00 suggest a wide range of expectations among analysts.